Article tools
Author information
Published in Volume 100, Issue 3 (August 1,1997)
J. Clin. Invest. 100(3): 530-537 (1997). doi:10.1172/JCI119562.
Copyright © 1997, The American Society for Clinical Investigation.

Research Article

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

M K Cavaghan, D A Ehrmann, M M Byrne and K S Polonsky

Department of Medicine, The University of Chicago and Pritzker School of Medicine, Chicago, Illinois 60637, USA.

Published August 1, 1997

Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM). Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion. We sought to determine the role of beta cell function in mediating improved glucose tolerance. Obese subjects with IGT received 12 wk of either 400 mg daily of troglitazone (n = 14) or placebo (n = 7) in a randomized, double-blind design. Study measures at baseline and after treatment were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (SI) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion rates during a graded glucose infusion, and beta cell glucose-sensing ability during an oscillatory glucose infusion. Troglitazone reduced integrated glucose and insulin responses to oral glucose by 10% (P = 0.03) and 39% (P = 0.003), respectively. SI increased from 1.3+/-0.3 to 2.6+/-0.4 x 10(-)5min-1pM-1 (P = 0.005). Average insulin secretion rates adjusted for SI over the glucose interval 5-11 mmol/liter were increased by 52% (P = 0.02), and the ability of the beta cell to entrain to an exogenous oscillatory glucose infusion, as evaluated by analysis of spectral power, was improved by 49% (P = 0.04). No significant changes in these parameters were demonstrated in the placebo group. In addition to increasing insulin sensitivity, we demonstrate that troglitazone improves the reduced beta cell response to glucose characteristic of subjects with IGT. This appears to be an important factor in the observed improvement in glucose tolerance.

This article Copyright © 1997, The American Society for Clinical Investigation.

Articles that cite
this article:

Die Insulinresistenz beim polyzystischen Ovar-Syndrom
Annika K. Schröder, Sascha Tauchert, Olaf Ortmann, Klaus Diedrich, Jürgen M. Weiss
Wien Klin Wochenschr 115(23):812. [CrossRef]

Cholesterol metabolism and pancreatic β-cell function
Michelle Fryirs, Philip J Barter, Kerry-Anne Rye
Curr Opin Lipidol 20(3):159. [CrossRef]

Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
Catherine Fiévet, Bart Staels
Curr Atheroscler Rep 11(4):281. [CrossRef]

Long-term glycaemic control with pioglitazone in patients with type 2 diabetes
I.W. Campbell
Int J Clinical Practice 58(2):192. [CrossRef]

Thiazolidinediones – some recent developments
Michael Stumvoll
Expert Opin Invest Drugs 12(7):1179. [CrossRef]

Thiazolidinediones in the treatment of Type 2 diabetes
Andrew S Greenberg, Anastassios G Pittas
Expert Opin Pharmacother 3(5):529. [CrossRef]

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study
T. M. Wallace, J. C. Levy, D. R. Matthews
Diabetic Med 21(6):568. [CrossRef]

Approaches to preventing mealtime hyperglycaemic excursions
D. E. Kelley
Diabetes Obes Metab 4(1):11. [CrossRef]

Thiazolidinediones: a new class of antidiabetic drugs
C. Day
Diabetic Med 16(3):179. [CrossRef]

Investigational agents that protect pancreatic islet β-cells from failure
Kathryn Aston-mourney, Joseph Proietto, Sofianos Andrikopoulos
Expert Opin Invest Drugs 14(10):1241. [CrossRef]

Expression and functional activity of PPARγ in pancreatic β cells
Hannah J Welters, Stuart C Mcbain, Moh Tadayyon, John H B Scarpello, Stephen A Smith, Noel G Morgan
Br J Pharmacol 142(7):1162. [CrossRef]

ß-cell function and anti-diabetic pharmacotherapy
Stefano Del prato, Cristina Bianchi, Piero Marchetti
Diabetes Metab Res Rev 23(7):518. [CrossRef]

Pioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β-cells
Y. Saitoh, C. Chun-ping, K. Noma, H. Ueno, M. Mizuta, M. Nakazato
Diabetes Obes Metab 10(7):564. [CrossRef]

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance
David A. Ehrmann, Kenneth S. Polonsky, Melissa K. Cavaghan
J Clin Invest 106(3):329. [CrossRef]

Preserving insulin secretion in Type 2 diabetes mellitus
Joseph Tibaldi
Expert Rev Endocrinol Metab 3(2):147. [CrossRef]

Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes
A. S. Greenberg, M. L. Mcdaniel
Eur J Clin Invest 32(s3):24. [CrossRef]

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes
R. N. Bergman, D. T. Finegood, S. E. Kahn
Eur J Clin Invest 32(s3):35. [CrossRef]

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology
J. E. Gerich
Eur J Clin Invest 32(s3):46. [CrossRef]

Islet adaptation to insulin resistance: mechanisms and implications for intervention
B. Ahren, G. Pacini
Diabetes Obes Metab 7(1):2. [CrossRef]

beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes
L. A. Leiter
Diabetic Med 22(8):963. [CrossRef]

The Role of Thiazolidinediones in the Treatment of Patients with Type 2 Diabetes Mellitus
Arshag D. Mooradian, Joe Chehade, Jerome E. Thurman
Treat Endocrinol 1(1):13. [CrossRef]

Thiazolidinediones and Insulin
Alvin Huang, Philip Raskin
Treat Endocrinol 4(4):205. [CrossRef]

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
M. Hanefeld
Int J Clinical Practice 61(s153):20. [CrossRef]

The importance of ?-cell management in type 2 diabetes
E. Standl
Int J Clinical Practice 61(s153):10. [CrossRef]

Targeting Insulin Resistance and -Cell Dysfunction: The Role of Thiazolidinediones
S. Del prato, P. Marchetti
diabetes technol ther 6(5):719. [CrossRef]

Current Views on the Mechanism of Action of Thiazolidinedione Insulin Sensitizers
Barry J. Goldstein
diabetes technol ther 1(3):267. [CrossRef]

Thiazolidinediones: A Review of Their Mechanisms of Insulin Sensitization, Therapeutic Potential, Clinical Efficacy, and Tolerability
Abu R. Vasudevan, Ashok Balasubramanyam
diabetes technol ther 6(6):850. [CrossRef]

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus
F. Ovalle, D. S. H. Bell
Diabetes Obes Metab 4(1):56. [CrossRef]

Cholesterol in islet dysfunction and type 2 diabetes
Liam R. Brunham, Janine K. Kruit, C. Bruce Verchere, Michael R. Hayden
J Clin Invest 118(2):403. [CrossRef]

NUCLEAR RECEPTORS AND THE CONTROL OF METABOLISM
Gordon A. Francis, Elisabeth Fayard, Frederic Picard, Johan Auwerx
Annu Rev Physiol 65(1):261. [CrossRef]

PPAR AND GLUCOSE HOMEOSTASIS
Frederic Picard, Johan Auwerx
Annu Rev Nutr 22(1):167. [CrossRef]

Dysfunctional fat cells, lipotoxicity and type 2 diabetes
R. A. Defronzo
Int J Clinical Practice 58(s143):9. [CrossRef]

Genetically defined pancreatic beta cell failure
Jan WA Smit, Michaela Diamant
phgs 3(5):669. [CrossRef]

New therapeutic approaches to reversing insulin resistance
Gabriele E. Sonnenberg, Theodore A. Kotchen
[CrossRef]

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus
Suzanne M. Strowig, Philip Raskin
Diabetes Obes Metab 7(6):633. [CrossRef]


Jean-Patrice Baillargeon, Maria Iuorno, John Nestler
CURR OPIN ENDOCRINOL DIABETES 9(4):303. [CrossRef]

Mechanisms linking obesity to insulin resistance and type 2 diabetes
Steven E. Kahn, Rebecca L. Hull, Kristina M. Utzschneider
Appl Opt 444(7121):840. [CrossRef]

Effects of Pioglitazone in Combination with Metformin or a Sulfonylurea Compared to a Fixed-Dose Combination of Metformin and Glibenclamide in Patients with Type 2 Diabetes
M. Comaschi, A. Demicheli, C. Di pietro, A. Bellatreccia, S. Mariz
Diabetes Tech Therap 9(4):387. [CrossRef]

β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment
Liam R Brunham, Janine K Kruit, Terry D Pape, Jenelle M Timmins, Anne Q Reuwer, Zainisha Vasanji, Brad J Marsh, Brian Rodrigues, James D Johnson, John S Parks
Nat Med 13(3):340. [CrossRef]

MECHANISMS OF INSULIN RESISTANCE AND NEW PHARMACOLOGICAL APPROACHES TO METABOLISM AND DIABETIC COMPLICATIONS
Richard Donnelly, Xianqin Qu
Clin Exp Pharmacol Physiol 25(2):79. [CrossRef]

Pharmacogenetics of thiazolidinedione therapy
Christina L Aquilante
phgs 8(8):917. [CrossRef]

Evaluation of ?-cell mass and function in the G�ttingen minipig
M. O. Larsen, B. Rolin, K. Raun, L. Bjerre knudsen, C. F. Gotfredsen, T. Bock
Diabetes Obes Metab 9(s2):170. [CrossRef]

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes
Hamiyet Yilmaz, Alptekin Gursoy, Mustafa Sahin, Nilgun Guvener demirag
Acta Diabetol 44(4):187. [CrossRef]

An examination of β-cell function measures and their potential use for estimating β-cell mass
S. E. Kahn, D. B. Carr, M. V. Faulenbach, K. M. Utzschneider
Diabetes Obes Metab [CrossRef]

Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the KATP channel and insulin secretion in rats
T.-J. Chang, W.-P. Chen, C. Yang, P.-H. Lu, Y.-C. Liang, M.-J. Su, S.-C. Lee, L.-M. Chuang
Diabetologica 52(6):1112. [CrossRef]